Therapeutic Proteins
- ️Sun Jan 01 2012
Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343–357
Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5:147–159
Waldmann TA (2003) Immunotherapy: past, present and future. Nat Med 9:269–277
Casadevall A, Dadachova E, Pirofski LA (2004) Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2:695–703
Carter PJ (2011) Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 317:1261–1269
Dimitrov DS (2010) Therapeutic antibodies, vaccines and antibodyomes. MAbs 2:347–356
Walsh G (2010) Biopharmaceutical benchmarks 2010. Nat Biotechnol 28:917–924
Leader B, Baca QJ, Golan DE (2008) Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 7:21–39
Dimitrov DS, Marks JD (2009) Therapeutic antibodies: current state and future trends—is a paradigm change coming soon? Methods Mol Biol 525:1–27
Ashkenazi A (2008) Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 7:1001–1012
Beck A, Reichert JM (2011) Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 3(5):415–416
Reichert JM (2011) Antibody-based therapeutics to watch in 2011. MAbs 3:76–99
Reichert JM (2010) Metrics for antibody therapeutics development. MAbs 2:695–700
Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497
Goeddel DV, Kleid DG, Bolivar F, Heyneker HL, Yansura DG, Crea R, Hirose T, Kraszewski A, Itakura K, Riggs AD (1979) Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc Natl Acad Sci USA 76:106–110
Feng Y, Dimitrov DS (2008) Monoclonal antibodies against components of the IGF system for cancer treatment. Curr Opin Drug Discov Devel 11:178–185
Wu H, Pfarr DS, Tang Y, An LL, Patel NK, Watkins JD, Huse WD, Kiener PA, Young JF (2005) Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 350:126–144
Skerra A (2007) Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 18:295–304
Chen W, Dimitrov DS (2009) Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors. Curr Opin HIV AIDS 4:112–117
Chen W, Zhu Z, Feng Y, Xiao X, Dimitrov DS (2008) Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J Mol Biol 382:779–789
Chen W, Zhu Z, Feng Y, Dimitrov DS (2008) Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci USA 105:17121–17126
Chen W, Xiao X, Wang Y, Zhu Z, Dimitrov DS (2010) Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates. Antiviral Res 88:107–115
Dimitrov DS (2009) Engineered CH2 domains (nanoantibodies). MAbs 1:26–28
Xiao X, Feng Y, Vu BK, Ishima R, Dimitrov DS (2009) A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors. Biochem Biophys Res Commun 387:387–392
Gong R, Vu BK, Feng Y, Prieto DA, Dyba MA, Walsh JD, Prabakaran P, Veenstra TD, Tarasov SG, Ishima R, Dimitrov DS (2009) Engineered human antibody constant domains with increased stability. J Biol Chem 284:14203–14210
Gong R, Wang Y, Feng Y, Zhao Q, Dimitrov DS (2011) Shortened engineered human antibody CH2 domains: increased stability and binding to the human neonatal receptor. J Biol Chem 286(3):27288–27293
Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M (2011) Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 10:101–111
Descotes J, Gouraud A (2008) Clinical immunotoxicity of therapeutic proteins. Expert Opin Drug Metab Toxicol 4:1537–1549
Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018–1028
Ewer SM, Ewer MS (2008) Cardiotoxicity profile of trastuzumab. Drug Saf 31:459–467
Chung CH (2008) Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 13:725–732
Winter MC, Hancock BW (2009) Ten years of rituximab in NHL. Expert Opin Drug Saf 8:223–235
Pendley C, Schantz A, Wagner C (2003) Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 5:172–179
Schellekens H (2008) How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 14:191–202
Onda M (2009) Reducing the immunogenicity of protein therapeutics. Curr Drug Targets 10:131–139
Baker MP, Jones TD (2007) Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Devel 10:219–227
Stas P, Lasters I (2009) Strategies for preclinical immunogenicity assessment of protein therapeutics. IDrugs 12:169–173
De Groot AS, McMurry J, Moise L (2008) Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol 8:620–626
Emi AN, de Carvalho JF, Artur Almeida SC, Bonfa E (2010) Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 38(2–3):82–89
Hangartner L, Zinkernagel RM, Hengartner H (2006) Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 6:231–243
Dixit R, Coats S (2009) Preclinical efficacy and safety models for mAbs: the challenge of developing effective model systems. IDrugs 12:103–108
Castillo J, Winer E, Quesenberry P (2008) Newer monoclonal antibodies for hematological malignancies. Exp Hematol 36:755–768
Mariani G, Fasolo A, De BE, Gianni L (2009) Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 6:93–104
Bedard PL, Piccart-Gebhart MJ (2008) Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. Clin Breast Cancer 8(Suppl 4):S157–S165
Hall PS, Cameron DA (2009) Current perspective—trastuzumab. Eur J Cancer 45:12–18
Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533–543
Norden AD, Drappatz J, Wen PY (2008) Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 7:1152–1160
Sachdev JC, Jahanzeb M (2008) Evolution of bevacizumab-based therapy in the management of breast cancer. Clin Breast Cancer 8:402–410
Patel DK (2008) Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 28:31S–41S
Tassev DV, Cheung NK (2009) Monoclonal antibody therapies for solid tumors. Expert Opin Biol Ther 9:341–353
Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I (2009) Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets 13:339–362
Presta LG (2008) Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 20:460–470
Jefferis R (2009) Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8:226–234
Labrijn AF, Aalberse RC, Schuurman J (2008) When binding is enough: nonactivating antibody formats. Curr Opin Immunol 20:479–485
Kiewe P, Thiel E (2008) Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs 17:1553–1558
Weber J (2009) Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 58:823–830
Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD (2008) CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 105:20410–20415
Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C (2009) TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 4:34–41
Feng Y, Xiao X, Zhu Z, Dimitrov DS (2010) Identification and characterization of a novel agonistic anti-DR4 human monoclonal antibody. MAbs 2:565–570
Zhang MY, Shu Y, Phogat S, Xiao X, Cham F, Bouma P, Choudhary A, Feng YR, Sanz I, Rybak S, Broder CC, Quinnan GV, Evans T, Dimitrov DS (2003) Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods 283:17–25
Choudhry V, Zhang MY, Sidorov IA, Louis JM, Harris I, Dimitrov AS, Bouma P, Cham F, Choudhary A, Rybak SM, Fouts T, Montefiori DC, Broder CC, Quinnan GV Jr, Dimitrov DS (2007) Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 363:79–90
Zhang MY, Dimitrov DS (2007) Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency. Curr Pharm Des 13:203–212
Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J (2008) Heterogeneity of monoclonal antibodies. J Pharm Sci 97:2426–2447
Birch JR, Racher AJ (2006) Antibody production. Adv Drug Deliv Rev 58:671–685
Zhou JX, Tressel T, Yang X, Seewoester T (2008) Implementation of advanced technologies in commercial monoclonal antibody production. Biotechnol J 3:1185–1200